...
首页> 外文期刊>Scientific reports. >Design and synthesis of 5-aryl-4-(4-arylpiperazine-1-carbonyl)-2 H -1,2,3-triazole derivatives as colchicine binding site inhibitors
【24h】

Design and synthesis of 5-aryl-4-(4-arylpiperazine-1-carbonyl)-2 H -1,2,3-triazole derivatives as colchicine binding site inhibitors

机译:为5-芳基-4-(4-芳基哌嗪-1-羰基)-2H -1,2,3-三唑衍生物的设计和合成作为血氯化汀结合位点抑制剂

获取原文

摘要

A series of 5-aryl-4-(4-arylpiperazine-1-carbonyl)-2H-1,2,3-triazol derivatives were designed as potential microtubule targeting agents. The regioselective alkylation of 5-aryl-4-(4-arylpiperazine-1-carbonyl)-2H-1,2,3-triazole was predicted by computations and confirmed by an unambiguous synthetic route. The antiproliferative activity of the synthesized compounds was tested in vitro using three human cancer cell lines and some compounds exhibited significant antiproliferative activity, which suggested the reasonability of introduction of the 1,2,3-triazole fragment. Among them, compound 7p showed highest activity with the IC50 values at nanomolar level towards all three cell lines, which were comparable to the positive control, CA-4. Tubulin polymerization assay, immunofluorescence studies, cell cycle analysis and competitive tubulin-binding assay strongly proved that 7p is a colchicine binding site inhibitor of tubulin. Thus, 7p was identified as a promising drug candidate for further development of colchicine binding site inhibitors.
机译:一系列5-芳基-4-(4-芳基哌嗪-1-羰基)-2H-1,2,3-三唑衍生物设计为潜在的微管靶向剂。通过计算预测5-芳基-4-(4-芳基哌嗪-1-羰基)-2H-1,2,3-三唑的区域选择性烷基化,并通过明确的合成路线证实。合成化合物的抗增殖活性在体外使用三种人癌细胞系进行测试,一些化合物表现出显着的抗增殖活性,这表明了引入1,2,3-三唑片段的合理性。其中,化合物7p显示出最高活性与纳米摩尔水平的IC 50值朝向所有三种细胞系,其与阳性对照,Ca-4相当。管蛋白聚合测定,免疫荧光研究,细胞循环分析和竞争小管蛋白结合测定强烈证明,7P是小植物蛋白的殖民苷元结合位点抑制剂。因此,7P被鉴定为有望的药物候选者,用于进一步发展殖民氨基结合位点抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号